152 related articles for article (PubMed ID: 30596218)
21. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
Dong LH; Zhang LJ; Wang WJ; Lei W; Sun X; Du JW; Gao X; Li GP; Li YF
Leuk Lymphoma; 2016 Jul; 57(7):1600-6. PubMed ID: 26726970
[TBL] [Abstract][Full Text] [Related]
22. Review on natural killer/T-cell lymphoma.
He X; Gao Y; Li Z; Huang H
Hematol Oncol; 2023 Apr; 41(2):221-229. PubMed ID: 34731509
[TBL] [Abstract][Full Text] [Related]
23. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma.
Suzuki R
Semin Hematol; 2014 Jan; 51(1):42-51. PubMed ID: 24468315
[TBL] [Abstract][Full Text] [Related]
24. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
Makita S; Tobinai K
Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
[TBL] [Abstract][Full Text] [Related]
25. Management of advanced NK/T-cell lymphoma.
Tse E; Kwong YL
Curr Hematol Malig Rep; 2014 Sep; 9(3):233-42. PubMed ID: 24924658
[TBL] [Abstract][Full Text] [Related]
26. [Incidence and treatment of extranodal natural killer/T-cell lymphoma nasal type. Hungarian experiences].
Bakos A; Szomor Á; Schneider T; Miltényi Z; Marton I; Borbényi Z; Pammer J; Krenács L; Bagdi E; Piukovics K
Orv Hetil; 2017 Oct; 158(41):1635-1641. PubMed ID: 29025287
[TBL] [Abstract][Full Text] [Related]
27. Extranodal natural killer/T-cell lymphoma: advances in the management.
Jaccard A; Hermine O
Curr Opin Oncol; 2011 Sep; 23(5):429-35. PubMed ID: 21743325
[TBL] [Abstract][Full Text] [Related]
28. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
[TBL] [Abstract][Full Text] [Related]
29. Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.
Kohrt H; Advani R
Leuk Lymphoma; 2009 Nov; 50(11):1773-84. PubMed ID: 19883307
[TBL] [Abstract][Full Text] [Related]
30. Risk stratification in extranodal natural killer/T-cell lymphoma.
Kohrt H; Lee M; Advani R
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1395-405. PubMed ID: 20836675
[TBL] [Abstract][Full Text] [Related]
31. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
[TBL] [Abstract][Full Text] [Related]
33. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
Jaccard A; Petit B; Girault S; Suarez F; Gressin R; Zini JM; Coiteux V; Larroche C; Devidas A; Thiéblemont C; Gaulard P; Marin B; Gachard N; Bordessoule D; Hermine O
Ann Oncol; 2009 Jan; 20(1):110-6. PubMed ID: 18701429
[TBL] [Abstract][Full Text] [Related]
34. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
35. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
[TBL] [Abstract][Full Text] [Related]
36. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
[TBL] [Abstract][Full Text] [Related]
37. Management of extranodal natural killer/t-cell lymphoma, nasal type.
Chaudhary RK; Bhatt VR; Vose JM
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):245-52. PubMed ID: 25659751
[TBL] [Abstract][Full Text] [Related]
38. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
39. A comparison of treatment modalities for nasal extranodal natural killer/T-cell lymphoma in early stages: The efficacy of CHOP regimen based concurrent chemoradiotherapy.
Cao J; Lan S; Shen L; Si H; Zhang N; Li H; Guo R
Oncotarget; 2017 Mar; 8(12):20362-20370. PubMed ID: 27901491
[TBL] [Abstract][Full Text] [Related]
40. Practical management of natural killer/T-cell lymphoma.
Tse E; Kwong YL
Curr Opin Oncol; 2012 Sep; 24(5):480-6. PubMed ID: 22691924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
